Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MicroRNA expression profile of different grade pancreatic neuroendocrine tumors

ABSTRACT: MicroRNA expression profile of different grade pancreatic neuroendocrine tumors

PROVIDER: PRJNA1104139 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR28789439.fastq.gz	Fastqsanger.gz
	SRR28789440.fastq.gz	Fastqsanger.gz
	SRR28789441.fastq.gz	Fastqsanger.gz
	SRR28789442.fastq.gz	Fastqsanger.gz
	SRR28789443.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

MicroRNA expression profile of different grade pancreatic neuroendocrine tumors

Project description:The grade of pancreatic neuroendocrine tumors principally influences therapy. Grading is currently done by the histological examination of biopsy samples, which is an invasive and time-consuming method. We performed an NGS on FFPE tumor tissue samples to find microRNAs that show a significant difference in expression according to grade, thus could be suitable for grade determination.

2024-08-02 | GSE265752 | GEO

DNA methylation and Panel sequencing for pancreatic neuroendocrine carcinomas (PanNECs) and pancreatic neuroendocrine tumors (PanNETs)

Project description:Pancreatic Neuroendocrine Neoplasms (PanNENs) are two subclasses: the well-differentiated, low to high-grade Pancreatic Neuroendocrine Tumors (PanNETs) and the poorly-differentiated, high-grade Pancreatic Neuroendocrine Carcinomas (PanNECs). DNA methylation and sequencing was performed for 57 PanNEN samples to decipher distinct methylation profiles separating PanNENs. Our study provides a robust and clinically applicable method to clearly distinguish PanNECs from PanNETG3s and improve patient stratification.

| EGAS00001005731 | EGA

microRNA profiling in different grading of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Project description:Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare and heterogeneous tumors presenting a wide spectrum of different clinical and biological characteristics. In these tumors, the histological evaluation is a crucial element of clinical management. Currently, tumor grading, determined by Ki-67 staining and mitotic counts, is the most reliable predictor of prognosis. This scoring method is time-consuming and a high reproducibility cannot be achieved. Novel approaches are needed to support histological evaluation and prognosis. In this study, starting from a microarray analysis, we defined the miRNAs signature for poorly differentiated NETs (G3) compared to well differentiated NETs (G1 and G2) consisting of 56 deregulated miRNAs. Moreover, we identified 8 miRNAs that were expressed in all GEP-NETs grades but at different level. Among these miRNAs, we found miR-96-5p that raised its expression levels from grade 1 to grade 3; inversely, its target FOXO1 was decrease from grade 1 to grade 3. Our results reveal that the miRNAs expression profile of GEP-NET correlates their expression with grading showing a potential advantage of miRNA quantification to aid clinicians in the classification of common GEP-NETs subtypes.

2020-08-04 | GSE135034 | GEO

Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors.

Project description:Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors.

| PRJNA736305 | ENA

LC-MS of Human Blood of Pancreatic neuroendocrine tumors

Project description:Pancreatic Neuroendocrine tumors are challenging to diagnose and often detected at advanced stages due to lack of specific and sensitive biomarkers. This study utilized proteomics as a valuable approach for cancer biomarker discovery, therefore, mass spectrometry-based proteomic profiling was conducted on plasma samples from 12 subjects (3 controls; 9 PanNET patients) to identify potential proteins capable of effectively distinguish PanNET from healthy controls. 13.2% of proteins were uniquely identified in PanNET, while 60% were commonly expressed in PanNET and controls. 17 proteins exhibiting significant differential expression between PanNET and controls were identified with downstream analysis.

2024-01-26 | PXD045045 | Pride

DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association

Project description:This study evaluate the methylation profile of 84 clinically sporadic pancreatic neuroendocrine tumors (PanNETs) with associated clinical and genomic information. We identified three subgroups of PanNETs, termed T1, T2 and T3, with distinct patterns of methylation. The T1 subgroup was enriched for functional tumors and ATRX, DAXX and MEN1 wild-type genotypes. The T2 subgroup contained tumors with mutations in ATRX, DAXX and MEN1 and recurrent patterns of chromosomal losses in half of the genome with no association between regions with recurrent LOH and methylation levels. T2 tumors were larger and had lower methylation in the MGMT gene body, which showed positive correlation with gene expression. The T3 subgroup harboured mutations in MEN1 with recurrent LOH of chromosome 11, was enriched for grade G1 tumors and showed histological parameters associated with better prognosis. Our results suggest a role for methylation in both driving tumorigenesis and potentially stratifying prognosis in PanNETs. These set of normal adjacent pancreata was compared to ICGC pancreatic neuroendocrine tumour methylation. We identified CpG sites located in promoter regions with low levels of methylation (beta value <0.3) in all normal adjacent pancreata and from those selected the most variable probes with a standard deviation >0.20 of DNA methylation levels across all tumors to identify sub-groups.

2021-02-16 | GSE149395 | GEO

microRNA expression of pancreatic tumors

Project description:Solid-pseudopapillary neoplasm of pancreas (SPN), ductal adenocarcinoma (PCA), neuroendocrine tumor (NET) and non-neoplastic pancreas. comparison with gene expression of tumors and non-tumors To investigate the specific microRNA expression of SPN compared to other types of pancreatic tumor, we analyzed large-scale microRNA expressioin analysis to identify the molecular signature that may affect SPN tumorigenesis with mRNA expression profiles. Differentially expressed microRNAs were analyzed on SPNs, PCAs, NETs and Non-neoplastic tissues.

2013-12-31 | E-GEOD-43796 | biostudies-arrayexpress

Transcriptome of human non-functional pancreatic neuroendocrine tumors (PanNETs)

Project description:Transcriptome of human non-functional pancreatic neuroendocrine tumors (PanNETs)

| PRJNA484008 | ENA

Genome-wide methylation profiling of sporadic Pancreatic Neuroendocrine Tumors

Project description:Pancreatic neuroendocrine tumors (PanNETs) account for 1-3% of all neoplasms of the pancreas. Epigenetic changes seem to be the main drivers of PanNET tumorigenesis. Indeed, the most frequent mutated genes in PanNETs are DAXX (Death domain associated protein 6), ATRX (Transcriptional Regulator ATRX) and MEN1 (menin 1), which are all involved in epigenetic regulation. The objective of the project is to study the epigenetic changes undergoing in PanNETs. Specifically, we aimed at investigating whether do exist biologically important epigenetic differences in PanNET, useful for a clinically relevant classification.

2022-11-30 | E-MTAB-11962 | biostudies-arrayexpress

Genome-wide methylation profiling of sporadic Pancreatic Neuroendocrine Tumors

2022-11-30 | E-MTAB-11965 | biostudies-arrayexpress